These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21242960)

  • 1. Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation.
    Feng M; Li Z; Aau M; Wong CH; Yang X; Yu Q
    Oncogene; 2011 May; 30(19):2242-51. PubMed ID: 21242960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
    Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
    Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins.
    Yu Q; Ciemerych MA; Sicinski P
    Oncogene; 2005 Oct; 24(47):7114-9. PubMed ID: 16103884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
    Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
    Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis.
    Liao DJ; Natarajan G; Deming SL; Jamerson MH; Johnson M; Chepko G; Dickson RB
    Oncogene; 2000 Mar; 19(10):1307-17. PubMed ID: 10713672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level.
    Wang Z; Liu M; Zhu H; Zhang W; He S; Hu C; Quan L; Bai J; Xu N
    Int J Oncol; 2010 Nov; 37(5):1315-21. PubMed ID: 20878079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein.
    Xiong J; Du Q; Liang Z
    Oncogene; 2010 Sep; 29(35):4980-8. PubMed ID: 20562918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.
    Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V
    Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of miR-21 by Ras in vivo and its role in tumor growth.
    Frezzetti D; De Menna M; Zoppoli P; Guerra C; Ferraro A; Bello AM; De Luca P; Calabrese C; Fusco A; Ceccarelli M; Zollo M; Barbacid M; Di Lauro R; De Vita G
    Oncogene; 2011 Jan; 30(3):275-86. PubMed ID: 20956945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Rb and Myc activation co-operate to suppress cyclin D1 and contribute to transformation.
    Marhin WW; Hei YJ; Chen S; Jiang Z; Gallie BL; Phillips RA; Penn LZ
    Oncogene; 1996 Jan; 12(1):43-52. PubMed ID: 8552398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1.
    Tan A; Bitterman P; Sonenberg N; Peterson M; Polunovsky V
    Oncogene; 2000 Mar; 19(11):1437-47. PubMed ID: 10723135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.
    Leslie K; Lang C; Devgan G; Azare J; Berishaj M; Gerald W; Kim YB; Paz K; Darnell JE; Albanese C; Sakamaki T; Pestell R; Bromberg J
    Cancer Res; 2006 Mar; 66(5):2544-52. PubMed ID: 16510571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation.
    Chen H; Liu J; Zhao CQ; Diwan BA; Merrick BA; Waalkes MP
    Toxicol Appl Pharmacol; 2001 Sep; 175(3):260-8. PubMed ID: 11559025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice.
    Wang Y; Thakur A; Sun Y; Wu J; Biliran H; Bollig A; Liao DJ
    Cancer Res; 2007 Apr; 67(8):3698-707. PubMed ID: 17440082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific protection against breast cancers by cyclin D1 ablation.
    Yu Q; Geng Y; Sicinski P
    Nature; 2001 Jun; 411(6841):1017-21. PubMed ID: 11429595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
    Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; L├╝scher B
    Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Myc-regulated microRNAs modulate E2F1 expression.
    O'Donnell KA; Wentzel EA; Zeller KI; Dang CV; Mendell JT
    Nature; 2005 Jun; 435(7043):839-43. PubMed ID: 15944709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-200c is a cMyc-activated miRNA that promotes nasopharyngeal carcinoma by downregulating PTEN.
    Chen P; Guo X; Zhang L; Zhang W; Zhou Q; Tian Z; Zheng Y; Liao Q; Wang H; Li G; Huang J; Li X
    Oncotarget; 2017 Jan; 8(3):5206-5218. PubMed ID: 28029649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
    Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
    Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
    Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
    Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.